Impact Factor 2020: 1.226 (@Clarivate Analytics)
5-Year Impact Factor: 2.285 (@Clarivate Analytics)
Immediacy Index: 2.645
  • Users Online: 157
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 14  |  Issue : 6  |  Page : 266-273

Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial


1 Sciences and Technology Park, Qazvin, Iran
2 Department of Surgery, Qazvin University of Medical Sciences, Qazvin, Iran
3 Department of Infectious Diseases, Clinical Research Development Unit, BouAliSina Hospital, Qazvin University of Medical Sciences, Qazvin, Iran
4 Department of Chemistry, Imam Khomeini International University, Qazvin, Iran
5 Department of Social Sciences School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
6 Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
7 Department of Infectious Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
8 Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
9 Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence Address:
Nematollah Gheibi
Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.318304

Get Permissions

Objective: To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences. Methods: A randomized, double-blind, placebo-controlled, multicenter clinical trial was performed at five hospitals. A total of 180 mild hospitalized patients with COVID-19 confirmed by PCR or chest image tests were enrolled and allocated to six arms including hydroxychloroquine 200 mg twice per day, placebo plus hydroxychloroquine 200 mg twice per day, single dose ivermectin (200 μg/kg), three low interval doses of ivermectin (200, 200, 200 μg/kg), single dose ivermectin (400 μg/kg), and three high interval doses of ivermectin (400, 200, 200 μg/kg). The primary endpoint of this trial was all-cause of mortality or clinical recovery. The radiographic findings, hospitalization and low O2 saturation duration, and hematological variables of blood samples were analyzed. Results: A total of 16.7% (5/30) and 20.0% (6/30) patients died in arms treated with hydroxychloroquine 200 mg twice per day and placebo plus hydroxychloroquine 200 mg twice per day, respectively, and a reduction in mortality rate in patients receiving ivermectin treatment to 0%, 10%, 0% and 3.3% for arms 1-4 were observed. Risk of mortality was also decreased about 15% in the ivermectin treated arms. Conclusions: Ivermectin as an adjunct reduces the rate of mortality, time of low O2 saturation, and duration of hospitalization in adult COVID-19 patients. The improvement of other clinical parameters shows that ivermectin, with a wide margin of safety, had a high therapeutic effect on COVID-19.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed46741    
    Printed158    
    Emailed6    
    PDF Downloaded1973    
    Comments [Add]    
    Cited by others 3    

Recommend this journal